Advertisement
Mylan CEO Faces Questions Over EpiPen Price Surge
ResumeLawmakers in the House and Senate are introducing a bill today that would force drug makers to justify price hikes of more than 10 percent.
The move follows the disclosure this summer that Mylan's life-saving EpiPen now costs more than $600, six times higher than the price when the company acquired the drug in 2007. Mylan CEO Heather Bresch will testify on Capitol Hill next week.
Here & Now's Jeremy Hobson speaks with business journalist Ali Velshi about what may come from Congress on this issue.
Guest
Ali Velshi, business journalist. He tweets @AliVelshi.
This segment aired on September 15, 2016.